Newsmeme!
Discover News you didn't know existed
ImClone Systems Incorporated (NASDAQ: IMCL) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) to broaden the use of ERBITUX(R) (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The application, submitted on August 29, 2008, was prepared in conjunction ...
NEW YORK----ImClone Systems Incorporated today announced that it has submitted an application to the U.S. Food and Drug Administration to broaden the use of ERBITUX® to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck .
ImClone Systems Incorporated (NASDAQ: IMCL) announced overall survival results from BMS CA225-099 (BMS-099), an open-label Phase 3 study of ERBITUX® (cetuximab) in combination with a taxane and carboplatin in the first-line treatment of all histological subtypes of advanced non-small cell lung cancer (NSCLC).
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |